Efficacy and safety on tenofovire therapy in patients with hepatitis B viral infections resistent to lamivudin

• Main Authors: Katanić N., Bojović K., Delić D., Simonović J., Malinić J., Milošević I.
• Format: Article
• Language: English
• Published: Medicinski fakultet Priština, Društvo lekara Kosova i Metohije Srpskog lekarskog društva 2015-01-01
• Series: Praxis Medica
• Subjects: chronic viral hepatitis B; Lamivudine; Tenofovir
• Online Access: http://scindeks-clanci.ceon.rs/data/pdf/0350-8773/2015/0350-87731501061K.pdf

Chronic viral hepatitis B (CHB) still represents a significant world health problem despite obligatory and worldwide immunization against infections of viral hepatitis B. In some patients with chronic viral hepatitis B infections, in the natural course of the disease, progression towards cirhossis and hepatocellular carcinoma is primarily targeted by antiviral CHB therapy stopping further progression of the disease. Today on the market there exist two classes of pharmnaceutical drugs for treatment of CHB: a) immunomodulatory therapy with conventional interferon alpha (INF) and PEGylated interferon alpha-2a, b) and oral antiviral therapy with nucleos( t)ide analogues. Lamivudine was for quite a period the only medicament available on our market for the treatment of HVB and in most of our patients led to the development of resistance. As of two years ago, a new oral analogue from the group of nucleotides is being registered in Serbia for market use: tenofovir disoproxil (TDF). In our work we have analysed 69 patients with chronic viral hepatitis B treated in the Clinic for Infectious and Tropical Diseases KCS Belgrade in the period between years 2012 and 2014. All patients involved in this reasearch were previously treated with LAM, and on subsequent development of resistance to LAM, TDF was used. TDF showed an excellent efficacy, a high resistance barrier and very few unwanted side effects over several years of treatment. Our experience with the use of this drug does not pertain to and acount for its long term use, in view of its brief availability on our market.